Company Overview and News
The broader indices continue to trade on a positive note this Thursday afternooon with the Nifty trading higher by 118 points at 10,802 and the Sensex gained 400 points at 35,579.
500325 FEDA 511389 535789 JUSTDIAL 532480 FEDS 523574 BJJQY GAILF 500570 FEDERALBNK RLNIY GRUH 538771 AXB RELCAPITAL ALBK FDBAY YYBKY 530005 JSWSTEEL AXBA BAJFINANCE TATASTEEL TATLY FRLDVR GAILY ANDHRABANK HINDCOPPER 500469 FSL 533150 500228 RELIANCE IDBI 533273 512573 532418 532856 VIDEOIND 532215 511288 500470 535648 AXISBANK PINCON RIGD INDIACEM TATAMOTORS 500034 500111 YESBANK UBNC 532809 570002 500116 AVANTI FRL IBN IDKQY 513599 532648 GRHFY 539207 AXBKY IBULHSGFIN ICICIBANK OBZIY GODREJPROP TTST OBEROIRLTY 532174 MANPASAND JSTQY TTM TIMETECHNO
The broader indices continue to trade on a positive note this Thursday afternooon with the Nifty trading higher by 111 points at 10,796 and the Sensex gained 375 points at 35,554.
500325 FEDA 511389 533137 DEN JUSTDIAL FEDS 523574 BJJQY GAILF 500570 FEDERALBNK SUNTV RLNIY GRUH 538771 AXB RELCAPITAL FDBAY YYBKY 530005 JSWSTEEL AXBA BAJFINANCE TATASTEEL TATLY FRLDVR GAILY HINDCOPPER 500469 FSL 533150 500228 RELIANCE 533273 512573 532856 VIDEOIND 532733 532215 511288 500470 535648 AXISBANK PINCON INOXWIND RIGD INDIACEM TATAMOTORS 500034 500111 YESBANK 532809 570002 AVANTI FRL IBN 513599 532648 GRHFY 539207 AXBKY ICICIBANK OBZIY GODREJPROP TTST OBEROIRLTY 532174 SNQVY 539083 MANPASAND JSTQY TTM TIMETECHNO
The broader indices are trading on a positive note this Thursday morning with the Nifty trading higher by 78 points at 10,762 and the Sensex gained 275 points at 35,454.
500325 511389 532832 533137 DEN JUSTDIAL 523574 BJJQY RLNIY GRUH 538771 AXB YYBKY JSWSTEEL AXBA BAJFINANCE TATASTEEL TATLY FRLDVR 500180 IBREALEST HINDCOPPER FSL 533150 500228 RELIANCE 533273 512573 532856 VIDEOIND 532215 511288 500470 535648 AXISBANK PINCON RIGD HDFCBANK 500034 YESBANK 532809 570002 HINDALCO AVANTI FRL IBN 513599 532648 GRHFY AXBKY HNDNF ICICIBANK OBZIY GODREJPROP TTST OBEROIRLTY HDB 532174 JSTQY 500440 TIMETECHNO
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
2018-06-11 - Asif
Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...